Validation of the Barcelona-MRI predictive model when PI-RADS v2.1 is used with transperineal prostate biopsies
Morote Robles, Juan (Universitat Autònoma de Barcelona. Departament de Cirurgia)
Paesano, Nahuel (Universitat Autònoma de Barcelona. Departament de Cirurgia)
Picola, Natàlia (Hospital Universitari de Bellvitge)
Muñoz Rodríguez, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Ruiz-Plazas, Xavier (Hospital Universitari Joan XXIII de Tarragona)
Muñoz Rivero, Marta Viridiana (Hospital Universitari Arnau de Vilanova)
Celma, Ana (Hospital Universitari Vall d'Hebron)
García-de Manuel, Gemma (Hospital Universitari de Girona Doctor Josep Trueta)
Miró, Berta (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Servian, Pol (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Abascal, Jose Maria (Parc de Salut MAR de Barcelona)

Data:	2024
Resum:	To validate the Barcelona magnetic resonance imaging predictive model (BCN-MRI PM) in men with pre-biopsy multiparametric MRI (mpMRI) reported with the Prostate Imaging Reporting and Data System (PI-RADS) v2. 1, followed by transrectal and transperineal prostate biopsies. Prospective analysis of 3,264 men with PSA >3. 0 ng/mL and/or abnormal digital rectal examination who were referred to ten participant centers in the csPCa early detection program of Catalonia (Spain), between 2021 and 2023. MpMRI was reported with the PI-RADS v2. 1, and 2- to 4-core MRI-transrectal ultrasound (TRUS) fusion-targeted biopsy of suspected lesions and/or 12-core systematic biopsy were conducted. 2,295 (70. 3%) individuals were referred to six centers for transrectal prostate biopsies, while 969 (39. 7%) were referred to four centers for transperineal prostate biopsies. CsPCa was classified whenever the International Society of Urologic Pathology grade group was 2 or higher. CsPCa was detected in 41% of transrectal prostate biopsies and in 45. 9% of transperineal prostate biopsies (p <0. 016). Both BCN-MRI PM calibration curves were within the ideal correlation between predicted and observed csPCa. Areas under the curve and 95% confidence intervals were 0. 847 (0. 830-0. 857) and 0. 830 (0. 823-0. 855), respectively (p = 0. 346). Specificities corresponding to 95% sensitivity were 37. 6 and 36. 8%, respectively (p = 0. 387). The Net benefit of the BCN-MRI PM was similar with both biopsy methods. The BCN-MRI PM has been successfully validated when mpMRI was reported with the PI-RADS v2. 1 and prostate biopsies were conducted via the transrectal and transperineal route.
Ajuts:	Instituto de Salud Carlos III PI20/01666
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Prostatic Neoplasms ; Magnetic Resonance Imaging ; Diagnosis
Publicat a:	International Braz J Urol, Vol. 50 (july 2024) , p. 595-604, ISSN 1677-6119

DOI: 10.1590/S1677-5538.IBJU.2024.0204
PMID: 39106115

10 p, 1.1 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats